Skip to Content

Generic Finacea Availability

Finacea is a brand name of azelaic acid topical, approved by the FDA in the following formulation(s):

FINACEA (azelaic acid - aerosol, foam;topical)

FINACEA (azelaic acid - gel;topical)

  • Manufacturer: BAYER HLTHCARE
    Approval date: December 24, 2002
    Strength(s): 15% [RLD]

Has a generic version of Finacea been approved?

An Authorized Generic version of Finacea has been approved. An Authorized Generic is a prescription drug that is produced by a brand company under a New Drug Application (NDA) and marketed as a generic under a private label. It is identical to the branded product in appearance, and unlike a generic, the Authorized Generic has exactly the same inactive ingredients.

List of authorized generic versions:

  • azelaic acid TOPICAL GEL .15 g/g
    Alvogen, Inc.
    NDC Code: 477810447

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Finacea. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Composition with azelaic acid
    Patent 6,534,070
    Issued: March 18, 2003
    Inventor(s): Patrick; Franke & Clemens; Günther & Jutta; Riedl
    Assignee(s): Schering Aktiengesellschaft
    The invention relates to a pharmaceutical composition having the following constituents: azelaic acid, polyacrylic acid, triacylglyceride, propylene glycol, polysorbate, soya lecithin, water and salts. The composition is a hydrogel which is suited for the treatment of rosacea, presbyderma, melasma or skin irritations.
    Patent expiration dates:
    • November 18, 2018
  • Mousse composition
    Patent 6,730,288
    Issued: May 4, 2004
    Inventor(s): Albert Zorko; Abram
    Assignee(s): Connetics Australia Pty Ltd
    A pharmaceutical aerosol foam composition including an effective amount of a pharmaceutically active ingredient; an occlusive agent; an aqueous solvent; and an organic cosolvent, the pharmaceutically active ingredient being insoluble in both water and the occlusive agent; the occlusive agent being present in an amount sufficient to form an occlusive layer on the skin, in use.
    Patent expiration dates:
    • September 8, 2019
      ✓ 
      Drug product
  • Penetrating pharmaceutical foam
    Patent 7,700,076
    Issued: April 20, 2010
    Inventor(s): Tamarkin; Dov & Friedman; Doron & Eini; Meir
    Assignee(s): Foamix, Ltd.
    The invention relates to an alcohol-free cosmetic or pharmaceutical foam composition comprising water, a hydrophobic solvent, a surface-active agent, a gelling agent, an active component selected from the group of urea, hydroxy acid and a therapeutic enhancer and a propellant. The foam further comprises active agents and excipients with therapeutic properties having enhanced skin penetration.
    Patent expiration dates:
    • September 18, 2027
      ✓ 
      Drug product
  • Penetrating pharmaceutical foam
    Patent 8,435,498
    Issued: May 7, 2013
    Assignee(s): Foamix Ltd.
    The invention relates to an alcohol-free cosmetic or pharmaceutical foam composition comprising water, a hydrophobic solvent, a surface-active agent, a gelling agent, an active component selected from the group of urea, hydroxy acid and a therapeutic enhancer and a propellant. The foam further comprises active agents and excipients with therapeutic properties having enhanced skin penetration.
    Patent expiration dates:
    • March 1, 2024
      ✓ 
      Patent use: TOPICAL TREATMENT OF INFLAMMATORY PAPULES AND PUSTULES OF MILD TO MODERATE ROSACEA
  • Foamable carriers
    Patent 8,722,021
    Issued: May 13, 2014
    Assignee(s): Foamix Ltd.
    The invention relates to an alcohol-free cosmetic or therapeutic foam carrier comprising water, a hydrophobic organic carrier, a foam adjuvant agent, a surface-active agent and a gelling agent. The cosmetic or therapeutic foam carrier does not contain aliphatic alcohols, making it non-irritating and non-drying. The alcohol-free foam carrier is suitable for inclusion of both water-soluble and oil soluble therapeutic and cosmetic agents.
    Patent expiration dates:
    • October 24, 2023
      ✓ 
      Drug product
  • Foamable composition and uses thereof
    Patent 8,900,554
    Issued: December 2, 2014
    Assignee(s): Foamix Pharmaceuticals Ltd.
    The present invention provides a safe and effective insecticide composition suitable for treating a subject infested with a parasitic anthropode or to prevent infestation by an arthropod. The insecticide composition is a foamable composition, including a first insecticide; at least one organic carrier selected from a hydrophobic organic carrier, a polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 5%, or about 5% to about 10%; or about 10% to about 20%; or about 20% to about 50% by weight; about 0.1% to about 5% by weight of a surface-active agent; about 0.01% to about 5% by weight of at least one polymeric agent selected from a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent; and (5) a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.
    Patent expiration dates:
    • October 24, 2023
      ✓ 
      Drug product
  • Antibiotic kit and composition and uses thereof
    Patent 9,211,259
    Issued: December 15, 2015
    Assignee(s): Foamix Pharmaceuticals Ltd.
    The present invention relates to a therapeutic kit to provide a safe and effective dosage of an antibiotic agent, including an aerosol packaging assembly including: a container accommodating a pressurized product; and an outlet capable of releasing the pressurized product as a foam, wherein the pressurized product comprises a foamable composition including: an antibiotic agent; at least one organic carrier selected from the group consisting of a hydrophobic organic carrier, an organic polar solvent, an emollient and mixtures thereof, at a concentration of about 2% to about 50% by weight, a surface-active agent, about 0.01% to about 5% by weight of at least one polymeric additive selected from the group consisting of a bioadhesive agent, a gelling agent, a film forming agent and a phase change agent, water; and liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.
    Patent expiration dates:
    • January 26, 2029
      ✓ 
      Patent use: TOPICAL TREATMENT OF INFLAMMATORY PAPULES AND PUSTULES OF MILD TO MODERATE ROSACEA

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • July 29, 2018 -

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide